News

EVMS and ODU join forces to create state’s largest health sciences program

Old Dominion University and Eastern Virginia Medical School are joining forces in an effort to grow local medical talent where there’s a great public need.

Together EVMS and ODU are now the Macon and Joan Brock Virginia Health Sciences at ODU.

The merger creates the largest health sciences program in the Commonwealth.

Come July 1, the integration will develop a larger pipeline for healthcare professionals in Hampton Roads by attracting and retaining homegrown talent and doubling the number of residency slots.

“All you’ve heard today is to better the community, better health care in the region,” said EVMS President Alfred Abuhamad, “so this is why there’s tremendous excitement on campus with EVMS about coming together with ODU.”

A 10-year agreement with ODU, EVMS and Sentara provides $350 million in total support for the new academic health sciences center. The merger expands healthcare capabilities while reducing disparities in Hampton Roads.

A $20 million endowment from the Ellmer family and a $20 million endowment from the Brock family will provide scholarships for local students who want to go into health sciences but are held back by financial hardship. ODU’s School of Nursing and College of Health Sciences were renamed the Ellmer School of Nursing and Ellmer College of Health Sciences.

“Those scholarships are encouraging students to stay and be here,” said ODU President Brian Hemphill. “Their residencies, our students that are going into nursing and physical therapy, we want them here.”

The integrated Virginia Health Sciences program will collectively serve 5,000 students.

 

Read more here.

Recent News

10/11/2024

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast

10/10/2024

RIVANNA initiates multi-site first-in-human study for Accuro XV musculoskeletal imaging system

RIVANNA®, developers of imaging-based medical solutions, has announced the launch of the first multi-site study employing the Accuro® XV musculoskeletal imaging system. This milestone follows a $30.5 million funding option executed in 2023 by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

10/09/2024

LifeNet Health’s Rapid Growth Continues with Acquisition of State-of-the-Art Virginia Beach Research Laboratory

A company that is a global leader in regenerative medicine has acquired a cutting-edge research laboratory in Virginia Beach. LifeNet Health will use the laboratory as a center of excellence for groundbreaking liver disease research and sports medicine applications. The dual function will provide better health solutions for a growing number of patients. Situated near